File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels

TitleOne-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels
Authors
Issue Date2006
PublisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfm
Citation
Antiviral Therapy, 2006, v. 11 n. 7, p. 909-916 How to Cite?
AbstractEntecavir and lamivudine are potent nucleoside analogues that can suppress hepatitis B virus (HBV) replication. However, the effects of these two antiviral agents on intrahepatic total HBV DNA and covalently closed circular DNA (cccDNA) are not known. In this study, we aimed to assess the effect of 48 weeks of entecavir/lamivudine therapy on intrahepatic total HBV DNA and cccDNA levels. Forty chronic hepatitis B patients, participating in two Phase III entecavir trials at our centre, were randomized to receive 48 weeks of either 0.5 mg once daily of entecavir (n=21) or 100 mg once daily of lamivudine (n=19). Their serological, virological and biochemical responses, as well as intrahepatic HBV DNA levels were monitored. There was no significant difference between entecavir and lamivudine therapy in terms of post-treatment serological, virological and biochemical responses. Both nucleoside analogues reduced serum viral load, intrahepatic total HBV DNA, and cccDNA by about 4.8 logs, 2 logs, and 1 log respectively. An increase in the proportion of intrahepatic HBV DNA in the form of cccDNA was seen after 48 weeks of therapy. In conclusion, both entecavir and lamivudine can successfully reduce intrahepatic HBV DNA and cccDNA. CccDNA becomes the dominant form of HBV DNA during viral suppression and is possibly responsible for viral rebound after short-term antiviral therapy. © 2006 International Medical Press.
Persistent Identifierhttp://hdl.handle.net/10722/78137
ISSN
2015 Impact Factor: 2.916
2015 SCImago Journal Rankings: 1.361
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorWong, DKHen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorNgai, VWSen_HK
dc.contributor.authorFung, Jen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:39:34Z-
dc.date.available2010-09-06T07:39:34Z-
dc.date.issued2006en_HK
dc.identifier.citationAntiviral Therapy, 2006, v. 11 n. 7, p. 909-916en_HK
dc.identifier.issn1359-6535en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78137-
dc.description.abstractEntecavir and lamivudine are potent nucleoside analogues that can suppress hepatitis B virus (HBV) replication. However, the effects of these two antiviral agents on intrahepatic total HBV DNA and covalently closed circular DNA (cccDNA) are not known. In this study, we aimed to assess the effect of 48 weeks of entecavir/lamivudine therapy on intrahepatic total HBV DNA and cccDNA levels. Forty chronic hepatitis B patients, participating in two Phase III entecavir trials at our centre, were randomized to receive 48 weeks of either 0.5 mg once daily of entecavir (n=21) or 100 mg once daily of lamivudine (n=19). Their serological, virological and biochemical responses, as well as intrahepatic HBV DNA levels were monitored. There was no significant difference between entecavir and lamivudine therapy in terms of post-treatment serological, virological and biochemical responses. Both nucleoside analogues reduced serum viral load, intrahepatic total HBV DNA, and cccDNA by about 4.8 logs, 2 logs, and 1 log respectively. An increase in the proportion of intrahepatic HBV DNA in the form of cccDNA was seen after 48 weeks of therapy. In conclusion, both entecavir and lamivudine can successfully reduce intrahepatic HBV DNA and cccDNA. CccDNA becomes the dominant form of HBV DNA during viral suppression and is possibly responsible for viral rebound after short-term antiviral therapy. © 2006 International Medical Press.en_HK
dc.languageengen_HK
dc.publisherInternational Medical Press. The Journal's web site is located at http://www.intmedpress.com/Journals/AVT/journals_avt_home.cfmen_HK
dc.relation.ispartofAntiviral Therapyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshChinaen_HK
dc.subject.meshDNA, Circular - analysisen_HK
dc.subject.meshDNA, Viral - analysisen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGuanine - analogs & derivatives - therapeutic useen_HK
dc.subject.meshHepatitis B virus - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - drug therapyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshLiver - virologyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshReverse Transcriptase Inhibitors - therapeutic useen_HK
dc.subject.meshTime Factorsen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleOne-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levelsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1359-6535&volume=11&spage=909&epage=916&date=2006&atitle=One-year+entecavir+or+lamivudine+therapy+results+in+reduction+of+hepatitis+B+virus+intrahepatic+covalently+closed+circular+DNA+levels.en_HK
dc.identifier.emailWong, DKH:danywong@hku.hken_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailFung, J:jfung@sicklehut.comen_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityWong, DKH=rp00492en_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityFung, J=rp00518en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid17302253-
dc.identifier.scopuseid_2-s2.0-33750964835en_HK
dc.identifier.hkuros126113en_HK
dc.identifier.hkuros130681-
dc.identifier.hkuros129870-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33750964835&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume11en_HK
dc.identifier.issue7en_HK
dc.identifier.spage909en_HK
dc.identifier.epage916en_HK
dc.identifier.isiWOS:000241975800009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridWong, DKH=7401535819en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridNgai, VWS=15061738300en_HK
dc.identifier.scopusauthoridFung, J=23091109300en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats